Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis

W. Zheng, Y.Q. Xiang, X.B. Li, Gabor S. Ungvari, H.F.K. Chiu, F. Sun, C. D’Arcy, X. Meng, Y.T. Xiang

    Research output: Contribution to journalArticle

    6 Citations (Scopus)

    Abstract

    © 2016 John Wiley & Sons, Ltd.Objective: The aim of this study was to examine the efficacy of huperzine A (HupA), an isolate of Huperzine serrata, in the treatment of cognitive deficits in schizophrenia spectrum disorders. Methods: PubMed, PsycINFO, Embase, Cochrane Library, Cochrane Controlled Trials Register, WanFang, Chinese Biomedical, and China Journal Net databases were searched from inception to 15 July 2015 for randomized controlled trials (RCTs) in English or Chinese of HupA augmentation of antipsychotic drug therapy versus placebo or ongoing antipsychotic treatment. Results: Twelve RCTs (n = 1117) lasting 11.7 ± 6.0 weeks met inclusion criteria. All had been conducted in China. HupA outperformed comparators on the following outcome measures: the Wechsler Memory Scale-Revised including memory quotient (weighted mean difference (WMD: 10.59; 95% confidence interval (CI): 5.65, 15.53; p <0.0001); Wechsler Adult Intelligence Scale-Revised including verbal intelligence quotient (IQ), performance IQ, and full IQ (WMD: 3.97 to 5.66; 95%CI: 0.20, 8.58; p = 0.01 to 0.00001); Wisconsin Card Sorting Test including response administer and non-perseverative errors (WMD: -12.79 to -12.29; 95%CI: -23.70, -0.88; p = 0.03 to 0.003). In studies using the Positive and Negative Syndrome Scale (n = 7)/Brief Psychiatric Rating Scale (n = 1), the differences in total score were significant (standard mean difference: -0.77; 95%CI: -1.27, -0.27; p = 0.002). All-cause discontinuation (risk ratio: 0.67; 95%CI: 0.36, 1.24; p = 0.20) and adverse events were similar between groups. Conclusions: This review suggests that adjunctive HupA is an effective choice for improving cognitive function for patients with schizophrenia spectrum disorders. More well-designed RCTs are needed to further confirm HupA's efficacy.
    Original languageEnglish
    Pages (from-to)286-295
    Number of pages10
    JournalHuman Psychopharmacology
    DOIs
    Publication statusPublished - 2016

    Fingerprint

    Meta-Analysis
    Schizophrenia
    Intelligence
    Confidence Intervals
    Randomized Controlled Trials
    Antipsychotic Agents
    China
    Brief Psychiatric Rating Scale
    Wechsler Scales
    Nuclear Family
    PubMed
    Cognition
    Libraries
    Odds Ratio
    Placebos
    Outcome Assessment (Health Care)
    huperzine A
    Databases
    Drug Therapy
    Therapeutics

    Cite this

    Zheng, W. ; Xiang, Y.Q. ; Li, X.B. ; Ungvari, Gabor S. ; Chiu, H.F.K. ; Sun, F. ; D’Arcy, C. ; Meng, X. ; Xiang, Y.T. / Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis. In: Human Psychopharmacology. 2016 ; pp. 286-295.
    @article{c1b767c9599448c8828b638aa2d04fcd,
    title = "Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis",
    abstract = "{\circledC} 2016 John Wiley & Sons, Ltd.Objective: The aim of this study was to examine the efficacy of huperzine A (HupA), an isolate of Huperzine serrata, in the treatment of cognitive deficits in schizophrenia spectrum disorders. Methods: PubMed, PsycINFO, Embase, Cochrane Library, Cochrane Controlled Trials Register, WanFang, Chinese Biomedical, and China Journal Net databases were searched from inception to 15 July 2015 for randomized controlled trials (RCTs) in English or Chinese of HupA augmentation of antipsychotic drug therapy versus placebo or ongoing antipsychotic treatment. Results: Twelve RCTs (n = 1117) lasting 11.7 ± 6.0 weeks met inclusion criteria. All had been conducted in China. HupA outperformed comparators on the following outcome measures: the Wechsler Memory Scale-Revised including memory quotient (weighted mean difference (WMD: 10.59; 95{\%} confidence interval (CI): 5.65, 15.53; p <0.0001); Wechsler Adult Intelligence Scale-Revised including verbal intelligence quotient (IQ), performance IQ, and full IQ (WMD: 3.97 to 5.66; 95{\%}CI: 0.20, 8.58; p = 0.01 to 0.00001); Wisconsin Card Sorting Test including response administer and non-perseverative errors (WMD: -12.79 to -12.29; 95{\%}CI: -23.70, -0.88; p = 0.03 to 0.003). In studies using the Positive and Negative Syndrome Scale (n = 7)/Brief Psychiatric Rating Scale (n = 1), the differences in total score were significant (standard mean difference: -0.77; 95{\%}CI: -1.27, -0.27; p = 0.002). All-cause discontinuation (risk ratio: 0.67; 95{\%}CI: 0.36, 1.24; p = 0.20) and adverse events were similar between groups. Conclusions: This review suggests that adjunctive HupA is an effective choice for improving cognitive function for patients with schizophrenia spectrum disorders. More well-designed RCTs are needed to further confirm HupA's efficacy.",
    author = "W. Zheng and Y.Q. Xiang and X.B. Li and Ungvari, {Gabor S.} and H.F.K. Chiu and F. Sun and C. D’Arcy and X. Meng and Y.T. Xiang",
    year = "2016",
    doi = "10.1002/hup.2537",
    language = "English",
    pages = "286--295",
    journal = "Human Psychopharmacology: Clinical and Experimental",
    issn = "0885-6222",
    publisher = "John Wiley & Sons",

    }

    Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis. / Zheng, W.; Xiang, Y.Q.; Li, X.B.; Ungvari, Gabor S.; Chiu, H.F.K.; Sun, F.; D’Arcy, C.; Meng, X.; Xiang, Y.T.

    In: Human Psychopharmacology, 2016, p. 286-295.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis

    AU - Zheng, W.

    AU - Xiang, Y.Q.

    AU - Li, X.B.

    AU - Ungvari, Gabor S.

    AU - Chiu, H.F.K.

    AU - Sun, F.

    AU - D’Arcy, C.

    AU - Meng, X.

    AU - Xiang, Y.T.

    PY - 2016

    Y1 - 2016

    N2 - © 2016 John Wiley & Sons, Ltd.Objective: The aim of this study was to examine the efficacy of huperzine A (HupA), an isolate of Huperzine serrata, in the treatment of cognitive deficits in schizophrenia spectrum disorders. Methods: PubMed, PsycINFO, Embase, Cochrane Library, Cochrane Controlled Trials Register, WanFang, Chinese Biomedical, and China Journal Net databases were searched from inception to 15 July 2015 for randomized controlled trials (RCTs) in English or Chinese of HupA augmentation of antipsychotic drug therapy versus placebo or ongoing antipsychotic treatment. Results: Twelve RCTs (n = 1117) lasting 11.7 ± 6.0 weeks met inclusion criteria. All had been conducted in China. HupA outperformed comparators on the following outcome measures: the Wechsler Memory Scale-Revised including memory quotient (weighted mean difference (WMD: 10.59; 95% confidence interval (CI): 5.65, 15.53; p <0.0001); Wechsler Adult Intelligence Scale-Revised including verbal intelligence quotient (IQ), performance IQ, and full IQ (WMD: 3.97 to 5.66; 95%CI: 0.20, 8.58; p = 0.01 to 0.00001); Wisconsin Card Sorting Test including response administer and non-perseverative errors (WMD: -12.79 to -12.29; 95%CI: -23.70, -0.88; p = 0.03 to 0.003). In studies using the Positive and Negative Syndrome Scale (n = 7)/Brief Psychiatric Rating Scale (n = 1), the differences in total score were significant (standard mean difference: -0.77; 95%CI: -1.27, -0.27; p = 0.002). All-cause discontinuation (risk ratio: 0.67; 95%CI: 0.36, 1.24; p = 0.20) and adverse events were similar between groups. Conclusions: This review suggests that adjunctive HupA is an effective choice for improving cognitive function for patients with schizophrenia spectrum disorders. More well-designed RCTs are needed to further confirm HupA's efficacy.

    AB - © 2016 John Wiley & Sons, Ltd.Objective: The aim of this study was to examine the efficacy of huperzine A (HupA), an isolate of Huperzine serrata, in the treatment of cognitive deficits in schizophrenia spectrum disorders. Methods: PubMed, PsycINFO, Embase, Cochrane Library, Cochrane Controlled Trials Register, WanFang, Chinese Biomedical, and China Journal Net databases were searched from inception to 15 July 2015 for randomized controlled trials (RCTs) in English or Chinese of HupA augmentation of antipsychotic drug therapy versus placebo or ongoing antipsychotic treatment. Results: Twelve RCTs (n = 1117) lasting 11.7 ± 6.0 weeks met inclusion criteria. All had been conducted in China. HupA outperformed comparators on the following outcome measures: the Wechsler Memory Scale-Revised including memory quotient (weighted mean difference (WMD: 10.59; 95% confidence interval (CI): 5.65, 15.53; p <0.0001); Wechsler Adult Intelligence Scale-Revised including verbal intelligence quotient (IQ), performance IQ, and full IQ (WMD: 3.97 to 5.66; 95%CI: 0.20, 8.58; p = 0.01 to 0.00001); Wisconsin Card Sorting Test including response administer and non-perseverative errors (WMD: -12.79 to -12.29; 95%CI: -23.70, -0.88; p = 0.03 to 0.003). In studies using the Positive and Negative Syndrome Scale (n = 7)/Brief Psychiatric Rating Scale (n = 1), the differences in total score were significant (standard mean difference: -0.77; 95%CI: -1.27, -0.27; p = 0.002). All-cause discontinuation (risk ratio: 0.67; 95%CI: 0.36, 1.24; p = 0.20) and adverse events were similar between groups. Conclusions: This review suggests that adjunctive HupA is an effective choice for improving cognitive function for patients with schizophrenia spectrum disorders. More well-designed RCTs are needed to further confirm HupA's efficacy.

    U2 - 10.1002/hup.2537

    DO - 10.1002/hup.2537

    M3 - Article

    SP - 286

    EP - 295

    JO - Human Psychopharmacology: Clinical and Experimental

    JF - Human Psychopharmacology: Clinical and Experimental

    SN - 0885-6222

    ER -